TNSN96005A1 - 2-(2-n-alcoxyphenyl)-purine-6-ones 9-substituees - Google Patents

2-(2-n-alcoxyphenyl)-purine-6-ones 9-substituees

Info

Publication number
TNSN96005A1
TNSN96005A1 TNTNSN96005A TNSN96005A TNSN96005A1 TN SN96005 A1 TNSN96005 A1 TN SN96005A1 TN TNSN96005 A TNTNSN96005 A TN TNSN96005A TN SN96005 A TNSN96005 A TN SN96005A TN SN96005 A1 TNSN96005 A1 TN SN96005A1
Authority
TN
Tunisia
Prior art keywords
alcoxyphenyl
purine
ones
substituees
substituted
Prior art date
Application number
TNTNSN96005A
Other languages
English (en)
Inventor
Ulrich Niewohner Dr
Erwin Bischoff Dr
Helmuth Schutz Dr
Elisabeth Perzborn Dr
Matthias Schramm Dr
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of TNSN96005A1 publication Critical patent/TNSN96005A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ON PREPARE DES 2 - (2 - N - ALCOXYPHENYL) PURINE-6- ONES 9-SUBSTITUEES PAR CYCLISATION D'IMIDAZOLES CONVENABLEMENT SUBSTITUEES ET CONVERSION DES PURINES AINSI OBTENUES. LES 2 - (2 - N-ALCOXYPHENYL) PURINE - 6 - ONES 9 - SUBSTITUEES PEUVENT ETRE UTILISEES COMME PRINCIPES ACTIFS DANS DES MEDICAMENTS, EN PARTICULIER DANS DES MEDICAMENTS DESTINES AU TRAITEMENT DES INFLAMMATIONS, DES MALADIES THROMBOEMBOLIQUES ET DES MALADIES CARDIO- VASCULAIRES.
TNTNSN96005A 1995-01-19 1996-01-17 2-(2-n-alcoxyphenyl)-purine-6-ones 9-substituees TNSN96005A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501480A DE19501480A1 (de) 1995-01-19 1995-01-19 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one

Publications (1)

Publication Number Publication Date
TNSN96005A1 true TNSN96005A1 (en) 2005-03-15

Family

ID=7751828

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN96005A TNSN96005A1 (en) 1995-01-19 1996-01-17 2-(2-n-alcoxyphenyl)-purine-6-ones 9-substituees

Country Status (30)

Country Link
US (1) US5866571A (fr)
EP (1) EP0722943A1 (fr)
JP (1) JPH08231546A (fr)
KR (1) KR960029335A (fr)
CN (1) CN1138583A (fr)
AR (1) AR002704A1 (fr)
AU (1) AU4097796A (fr)
BG (1) BG61729B1 (fr)
BR (1) BR9600149A (fr)
CA (1) CA2167349A1 (fr)
CO (1) CO4700524A1 (fr)
CZ (1) CZ16896A3 (fr)
DE (1) DE19501480A1 (fr)
EE (1) EE9600020A (fr)
FI (1) FI960226A (fr)
HR (1) HRP960009A2 (fr)
HU (1) HUP9600107A3 (fr)
IL (1) IL116771A (fr)
MA (1) MA23779A1 (fr)
NO (1) NO960221L (fr)
NZ (1) NZ280829A (fr)
PE (1) PE10597A1 (fr)
PL (1) PL312353A1 (fr)
SG (1) SG47379A1 (fr)
SK (1) SK7696A3 (fr)
SV (1) SV1996000004A (fr)
TN (1) TNSN96005A1 (fr)
TR (1) TR199600701A2 (fr)
YU (1) YU2896A (fr)
ZA (1) ZA96399B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6064072A (en) * 1997-05-12 2000-05-16 Cymer, Inc. Plasma focus high energy photon source
DE19838300A1 (de) * 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
AUPQ515700A0 (en) * 2000-01-19 2000-02-10 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds
ES2381862T3 (es) * 2000-09-06 2012-06-01 Mitsubishi Tanabe Pharma Corporation Preparaciones para administración por vía oral
CN100372536C (zh) * 2001-02-15 2008-03-05 田边三菱制药株式会社 在口腔中迅速崩解的片剂
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
CN1264843C (zh) * 2001-12-13 2006-07-19 第一阿斯比奥制药株式会社 具有pde7抑制作用的吡唑并嘧啶酮衍生物
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
WO2003087037A1 (fr) * 2002-04-05 2003-10-23 Merck & Co., Inc. Arylamides substituee
ES2749433T3 (es) 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
CA1303037C (fr) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Derives de purinone utilises comme bronchodilatateurs,vasodilatateurs et agents anti-allergiques
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents

Also Published As

Publication number Publication date
MA23779A1 (fr) 1996-10-01
AR002704A1 (es) 1998-04-29
US5866571A (en) 1999-02-02
FI960226A (fi) 1996-07-20
YU2896A (sh) 1999-03-04
EP0722943A1 (fr) 1996-07-24
JPH08231546A (ja) 1996-09-10
NO960221L (no) 1996-07-22
SG47379A1 (en) 1998-04-17
HRP960009A2 (en) 1997-12-31
CN1138583A (zh) 1996-12-25
KR960029335A (ko) 1996-08-17
CA2167349A1 (fr) 1996-07-20
TR199600701A2 (tr) 1996-08-21
SK7696A3 (en) 1996-08-07
FI960226A0 (fi) 1996-01-17
CO4700524A1 (es) 1998-12-29
HUP9600107A3 (en) 1999-06-28
IL116771A (en) 1999-06-20
NO960221D0 (no) 1996-01-18
IL116771A0 (en) 1996-05-14
DE19501480A1 (de) 1996-07-25
PE10597A1 (es) 1997-06-13
NZ280829A (en) 1998-04-27
CZ16896A3 (en) 1996-08-14
EE9600020A (et) 1996-08-15
SV1996000004A (es) 1997-02-19
BG61729B1 (bg) 1998-04-30
AU4097796A (en) 1996-07-25
HU9600107D0 (en) 1996-03-28
BR9600149A (pt) 1998-01-06
HUP9600107A2 (en) 1997-05-28
ZA96399B (en) 1996-08-14
BG100291A (bg) 1996-07-31
PL312353A1 (en) 1996-07-22

Similar Documents

Publication Publication Date Title
TNSN96005A1 (en) 2-(2-n-alcoxyphenyl)-purine-6-ones 9-substituees
CA2149329A1 (fr) Utilisation d'anticorps hybrides et radioisotopiques diriges contre l'antigene de restriction de la differenciation des lymphocytes b humains pour le traitement du lymphome b
TW262461B (fr)
TNSN96007A1 (fr) Purine - 6 - ones 2,9 - disubstituees
FI903106A0 (fi) Preventivsystem och -foerfarande.
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
EP0249736A3 (fr) Onguent pour le traitement des maladies de peau
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
FI862609A (fi) Akne motverkande produkt.
NO172043C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-2,3-butadienyl-triamioalkanderivater
IT1276162B1 (it) Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche
WO2000016786A3 (fr) Acide oxihumique et son utilisation dans le traitement de diverses conditions
ITMI922742A0 (it) Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
CA2189705A1 (fr) Utilisation de flupirtine pour la prevention et le traitement des maladies associees a la deficience du systeme cellulaire hematopoietique
IE870577L (en) Topical amide preparation
IT1184729B (it) Prodotti farmaceutico cosmetico,in particolare per la cura di acne e seborrea
EP0302303A3 (fr) Composés bicycliques, leur utilisation pharmaceutique, leur préparation et intermédiaires pour leur préparation
DE50202865D1 (de) Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
ATE255890T1 (de) Pantothensäure-enthaltende arzneimittel zur behandlung von entzündlichen gelenkserkrankungen
FR2427822A1 (fr) Medicament pour le traitement des maladies circulatoires, a base de 5-methyl-7-dimethylamino-s-triazolo (1,5-a) pyrimidine
Whitfield Black plague
TNSN96021A1 (fr) Indoles substitues
James Cidofovir recommended for approval for CMV retinitis
RU94042570A (ru) Антигипоксическое средство - сок проростков пшеницы